top of page
All posts
Alzheimer's
ANVISA
Author: Allan Matsui
Author: Jairo Utimi
Author: Claudia Cilento
Author: Nilva Bortoleto
BPF
Cannabidiol
Cancer
Cannabis
Coronavirus
Covid-19
challenges
Epilepsy
pharmaceutical
IFA
pharmaceutical industry
Inovatie
medicines
opportunities
Parkinson
pharmaceuticals
pharmaceutical industry
Author: Camille Rodrigues da Silva
Incremental innovation
Investments
Marketing
News
Incremental innovation
Good Manufacturing Practices
Search
Aug 30, 2024
Post-registration of medicines – opportunities and challenges
Feb 9, 2021
Unraveling the Abbreviated Development Path
Feb 9, 2021
Publication of the Public Consultation for the review of RDC 200 - what is new?
Feb 9, 2021
NEW REGULATORY FRAMEWORK OF API
Feb 9, 2021
What are the new expectations for the development of incremental products and medicines?
Feb 9, 2021
INCREMENTAL INNOVATION: How to prepare for the changes that will come with the revision of RDC 200
Feb 9, 2021
Why are 24% of drug registrations still rejected?
Feb 9, 2021
Cannabis: challenges and opportunities
Feb 9, 2021
NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?
Feb 9, 2021
What is important about the new regulatory framework for good manufacturing practices?
E-BOOKS
CONTEÚDOS EXCLUSIVOS PARA AUXILIAR EM
SEU TRABALHO
Acesse
bottom of page
